Tecemotide

DRACPC ID  DRACPC0058

Active Ingredients   Tecemotide

Description  A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells.

Synonyms  Emepepimut-S; BLP-25; BLP-25 Liposomal Vaccine; BLP25 Liposome Vaccine; BP1-7-KLH; EMD 531444; L-BLP25; Stimuvax; Glycine, L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-L-alanyl-L-histidylglycyl-L-valyl-L-threonyl-L-seryl-L-alanyl-L-prolyl-L-alpha-aspartyl-L-threonyl-L-arginyl-L-prolyl-L-alanyl-L-prolylglycyl-L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-N6-(1-oxohexadecyl)-L-lysyl-; Tecemotide

Type  Biotech

Disease  Prostate Cancer, Non-Small-Cell Lung

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  C124H203N33O38

Molecular Weight  2764.1

Active Sequence  STAPPAHGVTSAPDTRPAPGSTAPPXG

Sequence Length  27

Modification  X=Lys(palmitoyl)

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  16208013

DrugBank Accession Number  DB12568

NCI Thesaurus Code  C2195  

UNII  Q7Y026G2CX   GSRS

CAS  221214-84-2



Drug approval


Drug indication
    Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01423760 An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials Non-Small Cell Lung Cancer; Multiple Myeloma Not Applicable Treatment
NCT01496131 A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients Prostate Cancer Phase 2 Treatment
NCT00157196 A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease Carcinoma, Non-Small-Cell Lung; Lung Neoplasms Phase 2 Treatment
NCT01507103 A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy Rectal Cancer Phase 2 Treatment
NCT00157209 A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.